Sanofi India Limited has published its financial results for the quarter ended March 31, 2026, in compliance with SEBI regulations. The company reported total income from operations of ₹4,767 million for the period, with net profit after tax standing at ₹1,026 million and net profit before tax reaching ₹1,379 million. The basic and diluted earnings per share for the quarter were recorded at ₹44.55 each, based on a face value of ₹10 per share.

Regulatory Compliance and Publication

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sanofi India Limited published its financial results in Business Standard (English) and Sakal (Marathi) newspapers on April 29, 2026. The company notified both BSE Limited and The National Stock Exchange of India Limited about this newspaper publication through official communication signed by Haresh Vala, Company Secretary and Compliance Officer.

Financial Performance Analysis

The company's total comprehensive income for the quarter ended March 31, 2026, was ₹1,026 million. Equity share capital remained constant at ₹230 million across all reported periods. The reserves (excluding revaluation reserve) as shown in the audited balance sheet of the previous year stood at ₹7,262 million for the year ended December 31, 2025.

Quarterly Performance Comparison

When compared with the previous quarter ended December 31, 2025, Sanofi India showed improvement in several key metrics. Total income from operations increased from ₹4,226 million in Q3 FY26 to ₹4,767 million in Q4 FY26. Net profit after tax also rose from ₹617 million to ₹1,026 million during the same period. However, compared with the corresponding quarter of the previous year ended March 31, 2025, total income declined from ₹5,392 million, while net profit after tax decreased from ₹1,195 million.

Board Approval and Compliance

The financial results for the quarter ended March 31, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on April 28, 2026. The results have been prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013, read together with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India.

Source: None/Company/INE058A01010/621e5010f2044c32.pdf

Sanofi India Limited successfully concluded its 70th Annual General Meeting on April 29, 2026, with all 11 resolutions receiving overwhelming shareholder approval. The meeting, conducted virtually from 3:30 PM to 5:25 PM IST, witnessed significant leadership transitions and strong participation with 85.50% of outstanding shares being voted across all resolutions.

Meeting Overview and Participation

The AGM was attended by 72 members virtually, including 2 promoter representatives and 70 public shareholders. Mr. Sunny Gogiya (ACS 56804, CP 21563), Partner at M/s. SGGS & Associates, served as the scrutinizer and issued the official report on April 29, 2026. The remote e-voting facility was available from April 25, 2026 (9:00 AM IST) to April 28, 2026 (5:00 PM IST).

Leadership Transitions and Board Changes

The AGM marked significant leadership changes with Chairman Aditya Narayan concluding his tenure on April 29, 2026. Mr. Rahul Bhatnagar will assume the position of Chairman effective April 30, 2026. The meeting also saw the completion of Mrs. Usha Thorat's tenure as Independent Director and welcomed new appointments including Ms. Rajani Kesari and Mr. Siraj Chaudhry as Independent Directors.

Financial Resolutions and Dividend Approval

Shareholders approved key financial matters including the adoption of annual audited financial statements for the year ended December 31, 2025. The dividend resolution received exceptional support, confirming the payment of interim dividend of Rs. 75 per equity share and declaring a final dividend of Rs. 48 per equity share, totaling Rs. 123 per share for FY25.

Related Party Transaction Approvals

Two material related party transaction resolutions were approved with promoter groups abstaining from voting as per regulatory requirements. Both transactions with Sanofi-Aventis Singapore Pte. Limited and Sanofi Healthcare India Private Limited received approval rates above 99.82% from non-promoter shareholders.

Regulatory Compliance and Documentation

Company Secretary Haresh Vala (Membership No: A18246) ensured full regulatory compliance by filing the consolidated voting results with BSE and NSE under Regulation 30 of SEBI regulations. The scrutinizer's report was issued on April 29, 2026, confirming that all resolutions were duly passed with requisite majority. The voting results and scrutinizer's report are available on the company's website and NSDL portal, demonstrating strong shareholder confidence in the company's strategic direction and governance processes.